Cited by 340

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.

Identification of N-(4-Piperidinyl)-4-(2,6-dichlorobenzoylamino)-1 H-pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design

Open access

Wyatt, Paul G., Woodhead, Andrew J., Berdini, Valerio, Boulstridge, John A., Carr, Maria G., Cross, David M., Davis, Deborah J., Devine, Lindsay A., Early, Theresa R., Feltell, Ruth E., Lewis, E. Jonathan, McMenamin, Rachel L., Navarro, Eva F., O’Brien, Michael A., O’Reilly, Marc, Reule, Matthias, Saxty, Gordon, Seavers, Lisa C. A., Smith, Donna-Michelle, Squires, Matt S., Trewartha, Gary, Walker, Margaret T., Woolford, Alison J.-A.·2008·Journal of Medicinal Chemistry

DOI 10.1021/jm800382h

Open this paper in CoChat — free account

Abstract

The application of fragment-based screening techniques to cyclin dependent kinase 2 (CDK2) identified multiple (>30) efficient, synthetically tractable small molecule hits for further optimization. Structure-based design approaches led to the identification of multiple lead series, which retained the key interactions of the initial binding fragments and additionally explored other areas of the ATP binding site. The majority of this paper details the structure-guided optimization of indazole (6) using information gained from multiple ligand-CDK2 cocrystal structures. Identification of key binding features for this class of compounds resulted in a series of molecules with low nM affinity for CDK2. Optimisation of cellular activity and characterization of pharmacokinetic properties led to the identification of 33 (AT7519), which is currently being evaluated in clinical trials for the treatment of human cancers.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1021/jm800382h

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cancer Cell Cycles
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379
The retinoblastoma protein and cell cycle control
Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90385-2 · Cited by 4,862
Principles of CDK regulation
Morgan, D. O. (1995) · Nature · doi:10.1038/374131a0 · Cited by 3,284
Ligand efficiency: a useful metric for lead selection
Hopkins, A. L., Groom, C. R., & Alex, A. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03069-7 · Cited by 1,846
To cycle or not to cycle: a critical decision in cancer
Malumbres, M., & Barbacid, M. (2001) · Nature Reviews Cancer · doi:10.1038/35106065 · Cited by 1,468
Biochemical and Cellular Effects of Roscovitine, a Potent and Selective Inhibitor of the Cyclin‐Dependent Kinases cdc2, cdk2 and cdk5
Meijer, L., Borgne, A., Mulner, O., Chong, J. P. J., Blow, J. J., Inagaki, N., Inagaki, M., Delcros, J., & Moulinoux, J. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.t01-2-00527.x · Cited by 1,352
Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs).
Graña, X., & Reddy, E. P. (1995) · PubMed · Cited by 1,139
Distinct Roles for Cyclin-Dependent Kinases in Cell Cycle Control
van den Heuvel, S., & Harlow, E. (1993) · Science · doi:10.1126/science.8266103 · Cited by 1,092
A decade of fragment-based drug design: strategic advances and lessons learned
Hajduk, P. J., & Greer, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2220 · Cited by 1,064
Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery
Hann, M. M., Leach, A. R., & Harper, G. (2001) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci000403i · Cited by 877
Fragment-based lead discovery
Rees, D. C., Congreve, Murray, C. W., & Carr, R. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1467 · Cited by 798
Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice
Ortega, S., Prieto, I., Odajima, J., Martín, A., Dubus, P., Sotillo, R., Barbero, J. L., Malumbres, M., & Barbacid, M. (2003) · Nature Genetics · doi:10.1038/ng1232 · Cited by 796
Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6
Malumbres, M., Sotillo, R., Santamarı́a, D., Galán, J., Cerezo, A., Ortega, S., Dubus, P., & Barbacid, M. (2004) · Cell · doi:10.1016/j.cell.2004.08.002 · Cited by 793
Cyclin D-dependent kinases, INK4 inhibitors and cancer
Ortega, S., Malumbres, M., & Barbacid, M. (2002) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(02)00037-9 · Cited by 778
Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer
(1996) · Advances in cancer research · doi:10.1016/s0065-230x(08)60352-8 · Cited by 752
NPAT links cyclin E–Cdk2 to the regulation of replication-dependent histone gene transcription
Zhao, J., Kennedy, B. K., Lawrence, B. D., Barbie, D. A., Matera, A. G., Fletcher, J. A., & Harlow, E. (2000) · Genes & Development · doi:10.1101/gad.827700 · Cited by 665
Cdk2 Knockout Mice Are Viable
Berthet, C., Aleem, E., Coppola, V., Tessarollo, L., & Kaldis, P. (2003) · Current Biology · doi:10.1016/j.cub.2003.09.024 · Cited by 663
Cyclin E Ablation in the Mouse
Geng, Y., Yu, Q., Sicinska, E., Das, M., Schneider, J. E., Bhattacharya, S., Rideout, W. M., Bronson, R. T., Gardner, H., & Sicinski, P. (2003) · Cell · doi:10.1016/s0092-8674(03)00645-7 · Cited by 660
Recent Developments in Fragment-Based Drug Discovery
Congreve, M., Chessari, G., Tisi, D., & Woodhead, A. J. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8000373 · Cited by 611
Self-citation
The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases
Brown, N. R., Noble, M. E. M., Endicott, J. A., & Johnson, L. N. (1999) · Nature Cell Biology · doi:10.1038/15674 · Cited by 546
Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6
Toogood, P. L., Harvey, P. J., Repine, J. T., Sheehan, D. J., VanderWel, S. N., Zhou, H., Keller, P. R., McNamara, D. J., Sherry, D., Zhu, T., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049354h · Cited by 513
Molecular Recognition of Protein Kinase Binding Pockets for Design of Potent and Selective Kinase Inhibitors
Liao, J. J.-L. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm0608107 · Cited by 507
Proliferation of cancer cells despite CDK2 inhibition
Tetsu, O., & McCormick, F. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00053-9 · Cited by 466
Fragment-Based Lead Discovery Using X-ray Crystallography
Hartshorn, M. J., Murray, C. W., Cleasby, A., Frederickson, M., Tickle, I. J., & Jhoti, H. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0495778 · Cited by 422
N-(5-Chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2 H-pyran-4-yloxy)quinazolin-4-amine, a Novel, Highly Selective, Orally Available, Dual-Specific c-Src/Abl Kinase Inhibitor
Hennequin, L. F., Allen, J., Breed, J., Curwen, J., Fennell, M., Green, T. P., Lambert-van der Brempt, C., Morgentin, R., Norman, R. A., Olivier, A., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060434q · Cited by 364
A novel one-step, highly sensitive fluorometric assay to evaluate cell-mediated cytotoxicity
Nociari, M. M., Shalev, A., Benias, P., & Russo, C. (1998) · Journal of Immunological Methods · doi:10.1016/s0022-1759(98)00028-3 · Cited by 351
Theory and Applications of NMR-Based Screening in Pharmaceutical Research
Lepre, C. A., Moore, J. M., & Peng, J. W. (2004) · Chemical Reviews · doi:10.1021/cr030409h · Cited by 322
Oxindole-Based Inhibitors of Cyclin-Dependent Kinase 2 (CDK2): Design, Synthesis, Enzymatic Activities, and X-ray Crystallographic Analysis
Bramson, H. N., Corona, J., Davis, S. T., Dickerson, S. H., Edelstein, M., Frye, S. V., Gampe, R. T., Harris, P. A., Hassell, A., Holmes, W. D., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm010117d · Cited by 269
N-(Cycloalkylamino)acyl-2-aminothiazole Inhibitors of Cyclin-Dependent Kinase 2. N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a Highly Efficacious and Selective Antitumor Agent
Misra, R. N., Xiao, H.-Y., Kim, K. S., Lu, S., Han, W.-C., Barbosa, S. A., Hunt, J. T., Rawlins, D. B., Shan, W., Ahmed, S. Z., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0305568 · Cited by 252
Expression of NPAT, a novel substrate of cyclin E-CDK2, promotes S-phase entry
Zhao, J., Dynlacht, B., Imai, T., Hori, T.-A., & Harlow, E. (1998) · Genes & Development · doi:10.1101/gad.12.4.456 · Cited by 223
High-Resolution Crystal Structures of Human Cyclin-Dependent Kinase 2 with and without ATP: Bound Waters and Natural Ligand as Guides for Inhibitor Design
Schulze-Gahmen, U., De Bondt, H. L., & Kim, S.-H. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm960402a · Cited by 211
Structure-Based Generation of a New Class of Potent Cdk4 Inhibitors: New de Novo Design Strategy and Library Design
Honma, T., Hayashi, K., Aoyama, T., Hashimoto, N., Machida, T., Fukasawa, K., Iwama, T., Ikeura, C., Ikuta, M., Suzuki-Takahashi, I., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm0103256 · Cited by 203
SPR-based Fragment Screening: Advantages and Applications
Neumann, T., Junker, H.-D., Schmidt, K., & Sekul, R. (2007) · Current Topics in Medicinal Chemistry · doi:10.2174/156802607782341073 · Cited by 189
Identification of Novel p38α MAP Kinase Inhibitors Using Fragment-Based Lead Generation
Gill, A. L., Frederickson, M., Cleasby, A., Woodhead, S. J., Carr, M. G., Woodhead, A. J., Walker, M. T., Congreve, M. S., Devine, L. A., Tisi, D., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049575n · Cited by 186
Self-citation
Fragment‐based Approaches in Drug Discovery
(2006) · Methods and Principles in Medicinal Chemistry · doi:10.1002/3527608761 · Cited by 181
Involvement of Myc Activity in a G1/S-Promoting Mechanism Parallel to the pRb/E2F Pathway
Santoni-Rugiu, E., Falck, J., Mailand, N., Bartek, J., & Lukas, J. (2000) · Molecular and Cellular Biology · doi:10.1128/.20.10.3497-3509.2000 · Cited by 172
A Jekyll and Hyde kinase: roles for Cdk5 in brain development and disease
Cruz, J. C., & Tsai, L.-H. (2004) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2004.05.002 · Cited by 170
Specificity Determinants of Recruitment Peptides Bound to Phospho-CDK2/Cyclin A,
Lowe, E. D., Tews, I., Cheng, K. Y., Brown, N. R., Gul, S., Noble, M. E. M., Gamblin, S. J., & Johnson, L. N. (2002) · Biochemistry · doi:10.1021/bi0268910 · Cited by 162
Annual Reports in Medicinal Chemistry
(2008) · Annual Reports in Medicinal Chemistry · doi:10.1016/s0065-7743(08)00029-8 · Cited by 158
Pyrido[2,3-d]pyrimidin-7-one Inhibitors of Cyclin-Dependent Kinases
Barvian, M. R., Boschelli, D. H., Cossrow, J., Dobrusin, E. M., Fattaey, A., Fritsch, A., Fry, D. W., Harvey, P., Keller, P. R., Garrett, M. D., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000271k · Cited by 157
Review of UCN‐01 Development: A Lesson in the Importance of Clinical Pharmacology
Fuse, E., Kuwabara, T., Sparreboom, A., Sausville, E. A., & Figg, W. D. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005274549 · Cited by 113
Imidazo[1,2- a ]pyridines. Part 2 : SAR and optimisation of a potent and selective class of cyclin-dependent kinase inhibitors
Byth, K. F., Culshaw, J. D., Green, S. A., Oakes, S. E., & Thomas, A. P. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.02.015 · Cited by 113
CDK9: From Basal Transcription to Cancer and AIDS
Falco, G. D., & Giordano, A. (2002) · Cancer Biology & Therapy · doi:10.4161/cbt.1.4.6113 · Cited by 110
Fragment-based approaches to enzyme inhibition
Ciulli, A., & Abell, C. (2007) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2007.09.003 · Cited by 109
SAR and X-ray. A New Approach Combining Fragment-Based Screening and Rational Drug Design: Application to the Discovery of Nanomolar Inhibitors of Src SH2
Lesuisse, D., Lange, G., Deprez, P., Bénard, D., Schoot, B. M., Delettre, G., Marquette, J.-P., Broto, P., Jean‐Baptiste, V., Bichet, P., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm010927p · Cited by 90
The Proto-oncogene c-myc Acts through the Cyclin-dependent Kinase (Cdk) Inhibitor p27Kip1to Facilitate the Activation of Cdk4/6 and Early G1Phase Progression
Obaya, Á. J., Kotenko, I., Cole, M. D., & Sedivy, J. M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202528200 · Cited by 88
Flavopiridol in the treatment of chronic lymphocytic leukemia
Christian, B. A., Grever, M. R., Byrd, J. C., & Lin, T. S. (2007) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3282efb9da · Cited by 55
Inhibitors of Cyclin-dependent Kinases as Anti-tumor Agents
Smith, P. J., & Yue, E. W. (2006) · CRC Press eBooks · doi:10.1201/9781420005400 · Cited by 55
(R)-Roscovitine (CYC202, Seliciclib)
Galons, H., Bettayeb, K., & Meijer, L. (2006) · Enzyme inhibitors series/CRC enzyme inhibitors series · doi:10.1201/9781420005400.ch9 · Cited by 31
Transcription factors
Handel, M. L., & Girgis, L. (2001) · Best Practice & Research Clinical Rheumatology · doi:10.1053/berh.2001.0186 · Cited by 19
Cyclin-dependent kinase inhibitors: a survey of the recent patent literature
Pevarello, P., & Villa, M. (2005) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.15.6.675 · Cited by 14
Regulation of transcription during the cell cycle
Locker, J. (2003) · Garland Science eBooks · doi:10.4324/9780203450406-10 · Cited by 1

Targeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2559 · Cited by 2,576
From 2000 to Mid-2010: A Fruitful Decade for the Synthesis of Pyrazoles
Fustero, S., Sánchez-Roselló, M., Barrio, P., & Simón-Fuentes, A. (2011) · Chemical Reviews · doi:10.1021/cr2000459 · Cited by 1,155
The influence of lipophilicity in drug discovery and design
Arnott, J. A., & Planey, S. L. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.714363 · Cited by 868
Improving Drug Candidates by Design: A Focus on Physicochemical Properties As a Means of Improving Compound Disposition and Safety
Meanwell, N. A. (2011) · Chemical Research in Toxicology · doi:10.1021/tx200211v · Cited by 620
Fragment-Based Approaches in Drug Discovery and Chemical Biology
Scott, D. E., Coyne, A. G., Hudson, S. A., & Abell, C. (2012) · Biochemistry · doi:10.1021/bi3005126 · Cited by 460

See all 340

Authors: Wyatt, P. G., Woodhead, A. J., Berdini, V., Boulstridge, J. A., Carr, M. G., Cross, D. M., Davis, D. J., Devine, L. A., Early, T. R., Feltell, R. E., Lewis, E. J., McMenamin, R. L., Navarro, E. F., O’Brien, M. A., O’Reilly, M., Reule, M., Saxty, G., Seavers, L. C. A., Smith, D.-M., Squires, M. S., Trewartha, G., Walker, M. T., & Woolford, A. J.-A.
Venue: Journal of Medicinal Chemistry
Publisher: American Chemical Society (ACS)
Published: 2008-07-26
Volume: 51
Issue: 16
Pages: 4986-4999
ISSN: 0022-2623 (ISSN-L)
1520-4804
DOI: 10.1021/jm800382h
OpenAlex: W2149658883
Cited by: 340
References: 52
FWCI: 27.87
Type: journal article
Language: en
Open access: green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

Identification of N-(4-Piperidinyl)-4-(2,6-dichlorobenzoylamino)-1 H-pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Self-check

Citations

Cites

Cited by

Metadata

Record

About these checks

Data sources